Skip to main content
TipRanks
Go Ultimate75% OFF

Syndax Pharmaceuticals (1T3) Stock Price & Analysis

4 Followers

1T3 Stock Chart & Stats

€7.86-€0.48(-5.78%)
At close: 5:30 PM GMT+1
€10€12.5€15€17.5Aug 7Oct 9Oct 21Nov 2
Day’s Range
EUR 7.86 - EUR 7.86
52-Week Range
EUR 7.86 - EUR 21.66
Previous Close
EUR 8.34
Volume
N/A
Average Volume (3M)
235
Market Cap
EUR 749.61M
Enterprise Value
EUR 1.85B
Total Cash (Recent Filing)
EUR 427.10M
Total Debt (Recent Filing)
EUR 589.41M
Price to Earnings (P/E)
―
Beta
0.32
Next Earnings
Mar 02, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revuforj Commercial Momentum

Sustained Revuforj growth indicates expanding adoption rather than a single launch-related spike. Rising new-patient starts, prescriptions, account penetration, and repeat use support a broader commercial base that can compound revenue and strengthen the product’s position in targeted acute leukemia.

Market Leadership And Access

Dominant class share, broad formulary coverage, and adoption across large and community accounts create durable commercial advantages. These factors can reduce access friction, support physician familiarity, and help preserve Revuforj’s position as indications and patient populations expand.

Diversified Growth Pipeline

The company combines a growing marketed franchise with expansion opportunities in front-line disease, additional leukemia populations, chronic GVHD, lung cancer, and myelofibrosis. This breadth provides multiple paths to extend growth and reduces reliance on a single near-term clinical outcome.

Bears Say

Persistent Unprofitability

Despite higher revenue and very strong gross margin, Syndax remains far from breakeven. Continued operating losses can absorb the benefit of commercial growth, require sustained expense discipline, and delay the point at which the marketed portfolio can independently fund research and development.

Cash Burn And Funding Reliance

Large recurring cash outflows reduce financial flexibility while Syndax funds commercialization and several clinical programs. Although burn improved from prior years, continued negative free cash flow may require future financing or tighter capital allocation, potentially increasing dilution or limiting investment choices.

Leverage And Negative Equity

Higher debt combined with negative equity signals a materially weakened capital base and constrains resilience if operating losses persist. Leverage can increase financing pressure and reduce flexibility to support pipeline investment, commercial expansion, or unexpected development needs over the coming quarters.

Syndax Pharmaceuticals News

1T3 FAQ

What was Syndax Pharmaceuticals’s price range in the past 12 months?
Syndax Pharmaceuticals lowest stock price was €7.86 and its highest was €21.66 in the past 12 months.
What is Syndax Pharmaceuticals’s market cap?
Syndax Pharmaceuticals’s market cap is €749.61M.
When is Syndax Pharmaceuticals’s upcoming earnings report date?
Syndax Pharmaceuticals’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 102 days.
How were Syndax Pharmaceuticals’s earnings last quarter?
Syndax Pharmaceuticals released its earnings results on Nov 02, 2026. The company reported -€0.502 earnings per share for the quarter, missing the consensus estimate of -€0.46 by -€0.042.
Is Syndax Pharmaceuticals overvalued?
According to Wall Street analysts Syndax Pharmaceuticals’s price is currently Undervalued.
Does Syndax Pharmaceuticals pay dividends?
Syndax Pharmaceuticals does not currently pay dividends.
What is Syndax Pharmaceuticals’s EPS estimate?
Syndax Pharmaceuticals’s EPS estimate is -0.44.
How many shares outstanding does Syndax Pharmaceuticals have?
Syndax Pharmaceuticals has 90,028,260 shares outstanding.
What happened to Syndax Pharmaceuticals’s price movement after its last earnings report?
Syndax Pharmaceuticals reported an EPS of -€0.502 in its last earnings report, missing expectations of -€0.46. Following the earnings report the stock price went down -4.177%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals?
Hedge funds hold Syndax Pharmaceuticals shares: the largest hedge-fund position in Syndax Pharmaceuticals is 482,792,327 shares, and hedge funds increased their holdings by 93.6K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology